William M Kahane Net Worth

The estimated Net Worth of William M Kahane is at least $4.76 Millón dollars as of 3 October 2016. William Kahane owns over 351,952 units of Arcturus Therapeutics Inc stock worth over $503,520 and over the last 12 years William sold ARCT stock worth over $4,253,170.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

William Kahane ARCT stock SEC Form 4 insiders trading

William has made over 4 trades of the Arcturus Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently William sold 5,947,827 units of ARCT stock worth $124,785,410 on 7 October 2016.

The largest trade William's ever made was selling 5,947,827 units of Arcturus Therapeutics Inc stock on 7 October 2016 worth over $124,785,410. On average, William trades about 642,471 units every 45 days since 2013. As of 3 October 2016 William still owns at least 24,000 units of Arcturus Therapeutics Inc stock.

You can see the complete history of William Kahane stock trades at the bottom of the page.

What's William Kahane's mailing address?

William's mailing address filed with the SEC is 405 PARK AVENUE, 14TH FLOOR, , NEW YORK, NY, 10022.

Insiders trading at Arcturus Therapeutics Inc

Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch y Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.

What does Arcturus Therapeutics Inc do?

founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.

Complete history of William Kahane stock trades at Global Net Lease Inc y Arcturus Therapeutics Inc

Arcturus Therapeutics Inc executives and stock owners

Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Sassine,
  Chief Financial Officer, Director
• Joseph Payne,
  President, Chief Executive Officer, Director
• Joseph E. Payne M.Sc.,
  Founder, Pres, CEO & Director
• Dr. Steven George Hughes M.B.A., M.D.,
  Chief Medical Officer
• Dr. Padmanabh Chivukula,
  Founder, Chief Scientific Officer, COO & Sec.
• Andrew H. Sassine,
  CFO & Director
• Padmanabh Chivukula,
  Chief Operating Officer, Chief Scientific Officer
• Lance Kurata,
  Chief Legal Officer
• Karah Parschauer,
  Director
• Edward Holmes,
  Independent Director
• Peter Farrell,
  Independent Chairman of the Board
• Magda Marquet,
  Independent Director
• James Barlow,
  Independent Director
• Steven Hughes,
  Chief Development Officer
• Dr. Nirdosh Jagota Ph.D.,
  Exec. VP & Chief Regulatory Officer
• Kevin T. Skol,
  Sr. VP of Bus. Devel. & Alliance Management
• Neda Safarzadeh,
  Sr. Director and Head of Investor Relations/PR & Marketing
• Dr. Dushyant B. Varshney Ph.D.,
  Exec. VP & Chief Technology Officer
• Keith C. Kummerfeld CPA,
  VP of Fin. & Corp. Controller
• Capital Group, Lpluxor Capi...,
  
• William G Stanley,
  Director
• Leslie D Michelson,
  Director
• Susan E Manning,
  See Remarks
• William M Kahane,
  President and CEO
• Brian D Jones,
  CFO and Treasurer
• Nicholas S Schorsch,
  Director
• Robert Burns,
  Director
• Pad Chivukula,
  Chief Scientific Officer & COO
• Keith C Kummerfeld,
  See Remarks
• Andy Sassine,
  Chief Financial Officer
• Lance Kurata,
  Chief Legal Officer
• Pharmaceutical Inc. Ultragenyx,
  Director
• Jing L. Marantz,
  Director
• John Markels,
  Director
• Moncef Slaoui,
  Director